Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2026)
Aquestive Therapeutics has reported Cash & Equivalents over the past 9 years, most recently at $121.2 million for Q4 2025.
- For Q4 2025, Cash & Equivalents rose 69.36% year-over-year to $121.2 million; the TTM value through Dec 2025 reached $121.2 million, up 69.36%, while the annual FY2025 figure was $121.2 million, 69.36% up from the prior year.
- Cash & Equivalents for Q4 2025 was $121.2 million at Aquestive Therapeutics, down from $129.1 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $129.1 million in Q3 2025 and troughed at $14.7 million in Q1 2022.
- A 5-year average of $50.6 million and a median of $29.6 million in 2021 define the central range for Cash & Equivalents.
- Biggest five-year swings in Cash & Equivalents: crashed 48.31% in 2022 and later soared 300.56% in 2024.
- Year by year, Cash & Equivalents stood at $28.0 million in 2021, then dropped by 2.68% to $27.3 million in 2022, then fell by 12.47% to $23.9 million in 2023, then skyrocketed by 199.71% to $71.5 million in 2024, then skyrocketed by 69.36% to $121.2 million in 2025.
- Business Quant data shows Cash & Equivalents for AQST at $121.2 million in Q4 2025, $129.1 million in Q3 2025, and $60.5 million in Q2 2025.